Newsroom
The Pediatric Praziquantel Consortium completes its pivotal clinical Phase III trial
The Pediatric Praziquantel Consortium is pleased to announce the completion of its pivotal Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children suffering from schistosomiasis.
The positive results of the trial conducted in Côte d'Ivoire and Kenya, allow the program to progress towards regulatory file submission to the European Medicines Agency.
Read more in the Consortium’s full press release.
Please find the US version of this press release here.